34 related articles for article (PubMed ID: 30264404)
1. Non-monotone Exponential Time (NEXT) Model for the Longitudinal Trend of a Continuous Outcome in Clinical Trials.
Duan R; Chen K; Du Y; Kulkarni PM; Qu Y
Ther Innov Regul Sci; 2024 Jan; 58(1):127-135. PubMed ID: 37751063
[TBL] [Abstract][Full Text] [Related]
2. Dynamic development paths for expanding a proof-of-concept study to explore dose range.
Deng Q; Bai X; Ting N
Stat Med; 2018 Sep; 37(22):3244-3253. PubMed ID: 29926481
[TBL] [Abstract][Full Text] [Related]
3. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
Liu F; Walters SJ; Julious SA
BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
[TBL] [Abstract][Full Text] [Related]
4. Study design aspects and inter-subject variability in longitudinal clinical phase II dose-finding trials.
Kennes LN; Volkers G; Kralidis G
Pharm Stat; 2019 Mar; 18(2):248-259. PubMed ID: 30623569
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian design and analysis for dose-response using informative prior information.
Smith MK; Marshall S
J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
[TBL] [Abstract][Full Text] [Related]
6. Integrating dose estimation into a decision-making framework for model-based drug development.
Dunyak J; Mitchell P; Hamrén B; Helmlinger G; Matcham J; Stanski D; Al-Huniti N
Pharm Stat; 2018 Mar; 17(2):155-168. PubMed ID: 29322659
[TBL] [Abstract][Full Text] [Related]
7. Can a multiple ascending dose study serve as an informative proof-of-concept study?
Qu Y
Stat Med; 2019 Feb; 38(3):354-362. PubMed ID: 30264404
[TBL] [Abstract][Full Text] [Related]
8. Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Friedman LG; McKeehan N; Hara Y; Cummings JL; Matthews DC; Zhu J; Mohs RC; Wang D; Hendrix SB; Quintana M; Schneider LS; Grundman M; Dickson SP; Feldman HH; Jaeger J; Finger EC; Ryan JM; Niehoff D; Dickinson SL; Markowitz JT; Owen M; Travaglia A; Fillit HM
Neurology; 2021 May; 96(20):944-954. PubMed ID: 33674360
[TBL] [Abstract][Full Text] [Related]
9. Dose-Response-Time Data Analysis: An Underexploited Trinity.
Gabrielsson J; Andersson R; Jirstrand M; Hjorth S
Pharmacol Rev; 2019 Jan; 71(1):89-122. PubMed ID: 30587536
[TBL] [Abstract][Full Text] [Related]
10. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules.
Zohar S; Latouche A; Taconnet M; Chevret S
Comput Methods Programs Biomed; 2003 Oct; 72(2):117-25. PubMed ID: 12941516
[TBL] [Abstract][Full Text] [Related]
11. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
12. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
